Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Dual MAO and AChE Inhibitor
Ladostigil is a dual inhibitor of monoamine oxidase (MAO) and acetylcholinesterase (AChE), demonstrating IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. This compound exhibits neuroprotective, antioxidant, and anti-inflammatory properties, making it valuable for research in conditions such as depression and Alzheimer's disease. Additionally, Ladostigil features an alkyne functional group, enabling it to serve as a click chemistry reagent through copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
AChE Inhibitor
Norneostigmine is a potent inhibitor of acetylcholinesterase (AChE) with the ability to penetrate the blood-brain barrier. It demonstrates a 50% inhibition of mouse brain AChE within 10 minutes of treatment, exhibiting efficacy comparable to other known AChE inhibitors. This reagent is valuable for investigating memory disorders, including Alzheimer's disease and related cognitive impairments, facilitating research into potential therapeutic strategies. -
AChE Inhibitor
Zanapezil is a potent, reversible, and selective inhibitor of acetylcholine esterase (AChE). With an IC50 of 51.2 nM in rat cerebral cortex homogenates, Zanapezil effectively inhibits AChE activity, while also demonstrating moderate inhibition of muscarinic M1 and M2 receptor binding, with Ki values of 234 nM and 340 nM, respectively. This compound serves as a valuable tool for research focused on the early stages of Alzheimer's disease (AD). -
BChE Inhibitor
Broussonin A is a potent butyrylcholinesterase (BChE) inhibitor, exhibiting an IC50 of 4.16 µM. This diarylpropane natural product is derived from the bark of Broussonetia papyrifera through solid fermentation processes. Broussonin A is primarily utilized in research investigating neurodegenerative diseases and the modulation of cholinergic signaling pathways. Its inhibitory activity makes it a valuable tool for studying the role of BChE in various biological contexts. -
Acetylcholinesterase Inhibitor
Osmanthuside B is an acetylcholinesterase inhibitor derived from Pseuderanthemum carruthersii (Seem.) Guill. var. atropurpureum (Bull.) Fosb. This compound exhibits weak inhibitory activity against acetylcholinesterase, making it a valuable tool for research into neurotransmission processes and potential therapeutic applications in neurodegenerative diseases. Its effects on cholinergic signaling pathways can provide insights into mechanisms of action for various biochemical studies. -
AChE Inhibitor
Zanapezil free base is a potent, reversible, and selective inhibitor of acetylcholine esterase (AChE). It demonstrates significant AChE activity inhibition in homogenates of the rat cerebral cortex, with an IC50 value of 51.2 nM. Additionally, Zanapezil exhibits moderate inhibition of muscarinic M1 and M2 receptor binding, with Ki values of 234 nM and 340 nM, respectively. This compound is suitable for research focused on the early stages of Alzheimer's disease, contributing to the understanding of cholinergic dysfunction in neurodegenerative disorders. -
Cholinesterase Inhibitor
Velnacrine maleate is an orally active cholinesterase inhibitor that targets the enzyme acetylcholinesterase, thus increasing acetylcholine levels in the brain. This compound is primarily utilized in research studying Alzheimer's disease and its associated cognitive decline. Through modulation of cholinergic neurotransmission, Velnacrine maleate provides insights into potential therapeutic strategies for neurological disorders. -
AChE/BChE Inhibitor
Octahydroaminoacridine succinate is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). This compound is primarily utilized in Alzheimer's disease research, where modulation of cholinergic activity plays a crucial role in therapeutic strategies. Its ability to effectively inhibit these enzymes makes it a valuable tool for understanding the underlying mechanisms of neurodegeneration and developing potential treatments. -
MAO Inhibitor
ASS234 is a potent monoamine oxidase (MAO) inhibitor, targeting MAO-A and MAO-B with IC50 values of 5.2 nM and 43 nM, respectively. In addition to its primary activity, ASS234 also exhibits inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), with IC50 values of 350 nM and 460 nM, respectively. This compound can be utilized in research related to neurodegenerative diseases, mood disorders, and cholinergic signaling pathways. -
hAChE/hBChE Inhibitor
SD-6 is a potent and orally active inhibitor of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE), displaying IC50 values of 0.907 µM and 1.579 µM, respectively. This compound exhibits favorable blood-brain barrier permeability and is characterized by a lack of neurotoxicity. SD-6 is primarily utilized in research related to Alzheimer's disease, making it a valuable tool for investigating cholinergic signaling pathways and therapeutic strategies. -
BChE Inhibitor
BChE-IN-11 is a potent and selective non-competitive inhibitor of butyrylcholinesterase (BChE), exhibiting an IC50 of 2.1 μM. This compound is primarily utilized in research related to Alzheimer's disease, where it aids in the examination of cholinergic dysfunction. Its capacity to effectively inhibit BChE makes it a valuable tool for studying disease mechanisms and potential therapeutic strategies in neurodegenerative disorders. -
ChE Inhibitor
Rivastigmine carbamate impurity (3-Nitrophenyl ethyl(methyl)carbamate) is a byproduct of Rivastigmine, a potent cholinesterase (ChE) inhibitor. This compound selectively inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), demonstrating IC50 values of 0.037 μM and 4.15 μM, respectively. Rivastigmine carbamate impurity is primarily utilized in the investigation of cholinergic system modulation and the pharmacological profiling of cholinesterase inhibitors in neurodegenerative disease research. -
Cholinesterase (ChE) Inhibitor
Isorosmanol is an abietane-type diterpene that functions as an acetylcholinesterase (AChE) inhibitor. It exhibits antioxidant, neuroprotective, and neurotrophic properties, making it of interest in neurological research. Additionally, Isorosmanol has been shown to inhibit melanin synthesis, highlighting its potential applications in studies related to pigmentation and neurodegenerative diseases. -
AChE Inhibitor
Leptomerine is an alkaloid derived from the stems of Esenbeckia leiocarpa Engl. that functions as an acetylcholinesterase (AChE) inhibitor. With an IC50 of 2.5 μM, it exhibits significant anticholinesterase activity, potentially contributing to therapeutic strategies for Alzheimer’s disease. This compound is valuable for research aimed at understanding cholinergic dysfunction and developing cognitive-enhancing therapies. -
AChE Inhibitor
Velnacrine is a potent inhibitor of acetylcholinesterase (AChE), displaying an IC50 of 3.27 μM. This compound has demonstrated the ability to reverse scopolamine-induced amnesia in rat models, highlighting its potential in cognitive research. Additionally, Velnacrine exhibits acute toxicity with an LD50 of 65 mg/kg, warranting careful handling during experimental applications. -
AChE/BChE Inhibitor
AChE/BChE-IN-10 is a potent dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), demonstrating IC50 values of 0.176 μM and 0.47 μM, respectively. This compound exhibits favorable permeability across the blood-brain barrier and has been shown to inhibit amyloid-beta (Aβ) aggregation. AChE/BChE-IN-10 is valuable for research applications focused on Alzheimer’s disease and related neurodegenerative disorders. -
AChE Inhibitor
Acacetin-7-O-β-D-galactopyranoside is a flavonoid known for its inhibitory activity against acetylcholinesterase (AChE). This compound, isolated from the flower heads of Chrysanthemum morifolium, shows potential for use in Alzheimer’s disease research. Its ability to modulate AChE activity makes it a valuable tool for studying cholinergic signaling and neurodegenerative processes. -
AChE Inhibitor
Carlina oxide functions as an acetylcholinesterase (AChE) inhibitor, exhibiting significant cytotoxic properties towards various cell lines, including human dermis, HCT116, and MDA-MB231. Additionally, it demonstrates potent larvicidal activity against Culex pipiens larvae, with an LC50 value of 1.39 μg/mL. This compound may be utilized in research contexts focusing on neurobiology, entomology, and cancer studies. -
Fungal Meroterpenoid/AChE inhibitor
Territrem B is a fungal meroterpenoid that serves as an irreversible inhibitor of acetylcholinesterase (AChE). It is isolated from Aspergillus terreus and exhibits significant neurotoxic activity. This compound is valuable for studying AChE-related pathways and can aid in the development of therapeutic agents for neurological disorders. -
AChE Inhibitor
ACHE-IN-38 is a potent inhibitor of acetylcholinesterase (AChE), acting to prevent the breakdown of the neurotransmitter acetylcholine (ACh). By inhibiting AChE, this compound enhances cholinergic transmission and has potential applications in addressing cognitive deficits associated with Alzheimer's Disease. It serves as a valuable tool in neuroscience research focused on memory disorders and cholinergic system modulation. -
BChE Inhibitor
Z32439948 is a butyrylcholinesterase (BChE) inhibitor with an IC50 of 1.4 μM against human BChE. This compound, a derivative of m-sulfamoylbenzamide, demonstrates neuroprotective properties, particularly against glutamate-induced toxicity in SH-SY5Y neuronal cell lines. Z32439948 is valuable for research in neurodegenerative disease models and therapeutic strategies targeting cholinergic dysfunction. -
AChE/BChE Inhibitor
AChE/BChE-IN-1 is a potent dual inhibitor of Acetylcholinesterase (AChE) and Butyrylcholinesterase (BChE), demonstrating IC50 values of 1.06 nM and 7.3 nM, respectively, for human enzymes. This compound exhibits brain penetrance and is also characterized by its antioxidant properties. AChE/BChE-IN-1 is valuable for research focused on Alzheimer’s disease and related neurological disorders, providing insights into cholinergic system modulation. -
AChE/BuChE Inhibitor
AChE/BuChE-IN-4 is a multitarget-directed inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 2.08 μM and 7.41 μM, respectively. This compound plays a significant role in studies related to neurodegenerative disorders and cholinergic signaling pathways. Its dual inhibition of AChE and BuChE makes it a valuable tool for research into therapeutic strategies for diseases such as Alzheimer's and other cognitive impairments. -
Ache Inhibitor
Dehydrodicentrine is an aporphine alkaloid that acts as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 2.98 μM. This compound is derived from the root of S. epigaea and demonstrates potential in studies related to neurological disorders and pain management. Its ability to modulate AChE activity makes it a valuable tool for research applications focused on cholinergic neurotransmission. -
Cholinesterase Inhibitor
SB-1436 is a potent cholinesterase inhibitor targeting acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 0.176 μM and 0.37 μM, respectively. It inhibits these enzymes in a non-competitive manner, exhibiting Kis of 0.046 μM for AChE and 0.115 μM for BChE. Additionally, SB-1436 significantly reduces the self-aggregation of amyloid-beta (Aβ), making it a valuable tool for research in neurological diseases and related therapeutic applications. -
AChE Inhibitor
AChE-IN-27 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 0.19 µM. This compound is specifically designed for research into neurological disorders, making it valuable for studies related to Alzheimer's disease, dementia, ataxia, and myasthenia gravis. Its ability to inhibit AChE provides a useful tool for investigating cholinergic signaling and developing potential therapeutic strategies for these conditions. -
AChE/BChE Inhibitor
Dehydrodiscretamine chloride is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 17.8 μM and 118.8 μM, respectively. This compound also possesses antioxidant activity, making it relevant for research into neurodegenerative diseases. Its potential applications include studies focused on Alzheimer’s disease and exploring pathways of cholinergic dysfunction. -
BChE Inhibitor
BChE-IN-7 is a selective inhibitor of butyrylcholinesterase (BChE) that effectively penetrates the blood-brain barrier. With an IC50 of 0.06 μM for BChE, this reversible inhibitor demonstrates significant neuroprotective effects against toxic amyloid-beta species in neuronal-like cells. It serves as a valuable tool for research in neurodegenerative diseases and the modulation of cholinergic pathways. -
AChE Inhibitor
Lycoramine hydrobromide is a potent acetylcholinesterase (AChE) inhibitor derived from Lycoris radiata. This compound serves as a valuable tool in the study of neurological disorders by enhancing cholinergic signaling through the inhibition of AChE activity. Its application in research includes investigating cognitive function, Alzheimer's disease, and other conditions associated with cholinergic deficits. -
BChE Inhibitor
BChE-IN-6 is a potent butyrylcholinesterase (BChE) inhibitor, exhibiting a Ki of 0.182 μM. This compound possesses chelating properties for Zn2+, making it a valuable tool for studying metal interactions in biological systems. BChE-IN-6 is primarily utilized in Alzheimer's disease research, aiding in the investigation of cholinergic dysfunction and potential therapeutic interventions. -
Acetylcholinesterase Inhibitor
Pirimiphos ethyl is an organophosphorus compound that functions as an acetylcholinesterase inhibitor. Its primary biological activity involves disrupting the normal hydrolysis of acetylcholine, resulting in prolonged neurotransmission at cholinergic synapses. This reagent is utilized extensively in agricultural research to study the effects of pesticide exposure on neurological pathways and to assess the ecological impact of pesticide application. -
AChE-MAO B Inhibitor
Dual AChE-MAO B-IN-2 is a powerful inhibitor of both acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), exhibiting IC50 values of 0.12 µM and 0.01 µM, respectively. This dual inhibition profile suggests its significant potential in the study and development of therapeutic strategies for Alzheimer's disease. Researchers can utilize Dual AChE-MAO B-IN-2 to explore mechanisms related to cholinergic dysfunction and oxidative stress in neurodegenerative conditions. -
AchE Inhibitor
Pumiloside is a natural compound isolated from Nauclea officinalis that functions as an acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 value of 118.36 μM. This compound is of significant interest for research applications related to neurodegenerative disorders, where modulation of cholinergic signaling may be beneficial. Pumiloside's ability to inhibit AChE positions it as a potential candidate for the development of therapeutic agents targeting cognitive decline. -
hBChE Inhibitor
Echothiopate iodide is a potent inhibitor of human butyrylcholinesterase (hBChE), known for its ability to prolong cholinergic activity. As a long-acting anticholinesterase agent, this compound is particularly relevant in studies related to glaucoma and acetylcholine signaling pathways. Its inhibitory effects make it a valuable tool for investigating cholinergic modulation and potential therapeutic interventions in related disorders. -
AChE Inhibitor
AChE-IN-7 is a highly selective and potent inhibitor of acetylcholinesterase with an eeAChE IC50 value of 0.045 μM and an eeBuChE IC50 of 19.68 μM. This compound demonstrates promising in vivo and in vitro safety profiles, along with favorable pharmacokinetic characteristics and high bioavailability (F = 55.5%). Additionally, AChE-IN-7 exhibits significant permeability across the blood-brain barrier, making it a valuable tool for research into neurological disorders and therapeutic strategies targeting cholinergic signaling. -
AChE Inhibitor
AChE-IN-44 is a potent acetylcholinesterase (AChE) inhibitor. It effectively enhances cholinergic neurotransmission by inhibiting the breakdown of acetylcholine, making it valuable for research in neurodegenerative diseases such as Alzheimer's. Additionally, AChE-IN-44 can be transformed into the thiazole salt derivative, AChE inhibitor Tat2, expanding its potential applications in pharmacological studies. -
BuChE Inhibitor
BuChE-IN-3 is a selective inhibitor of butyrylcholinesterase (BuChE) with an IC50 of 8.3 nM. This compound demonstrates neuroprotective properties and exhibits mild antioxidant activity, making it suitable for studies related to neurodegenerative diseases. Its favorable lipophilicity and low toxicity profile further support its potential in chemical research applications aimed at exploring BuChE's role in various biological processes. -
Cholinesterase (ChE) Inhibitor
Echimidine N-oxide is a pyrrolizidine alkaloid that serves as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 0.347 mM. This compound is utilized in research applications focusing on neurological disorders and cholinergic system modulation. Its inhibitory activity on ChE provides valuable insights into potential therapeutic strategies for conditions associated with cholinergic dysregulation. -
ChEs/MAOs Inhibitor
ChEs/MAOs-IN-2 is a potent inhibitor of cholinesterases and monoamine oxidases, exhibiting IC50 values of 0.10 µM for MAO-A, 0.20 µM for MAO-B, 0.30 µM for acetylcholinesterase (AChE), and 0.40 µM for butyrylcholinesterase (BChE). This compound demonstrates significant biological activity relevant to neurodegenerative diseases, particularly Alzheimer's disease, and serves as a valuable tool for research into therapeutic strategies targeting these enzymes. -
AChE Inhibitor
Scutellarein 4'-methyl ether 7-O-glucuronide is a flavonoid compound that acts as an inhibitor of acetylcholinesterase (AChE), with an IC50 value of 1 mg/mL. Isolated from Plectranthus barbatus, this compound exhibits antioxidant properties and is significant for research into neurological disorders, particularly Alzheimer's disease. Its dual function as an AChE inhibitor and antioxidant makes it valuable for studies exploring therapeutic strategies in cognitive health. -
AChE Inhibitor
Rivastigmine metabolite (NAP 226-90) is an acetylcholinesterase (AChE) inhibitor that plays a significant role in the modulation of cholinergic neurotransmission. This compound is a key metabolite formed in the kidney and is of particular interest for research into Alzheimer's Disease. Its inhibitory action on AChE highlights its potential for studying therapeutic approaches in neurodegenerative conditions characterized by cholinergic deficits. -
Acetylcholinesterase Inhibitor
Protopine hydrochloride is a reversible and competitive inhibitor of acetylcholinesterase. This isoquinoline alkaloid demonstrates significant anti-inflammatory, antimicrobial, anti-angiogenic, and anti-tumor properties. It can be utilized in various research applications, particularly in studies related to neurodegenerative diseases, cancer, and inflammatory disorders. -
AChE Inhibitor
Stemoninine is a lycoris alkaloid that acts as an inhibitor of acetylcholinesterase (AChE), exhibiting a significant inhibitory effect with an IC50 value of 5.52 μM. This compound demonstrates potential antitussive properties, making it a valuable reagent for research involving respiratory conditions and cholinergic signaling pathways. Its ability to modulate AChE activity is important for studies focusing on neurodegenerative diseases and synaptic transmission. -
ChE Inhibitor
Hexafluorenium dibromide is a potent cholinesterase (ChE) inhibitor, exhibiting a pI50 value of 6.96 and a Ki value of 2.4 nM for human plasma cholinesterase. This compound is primarily utilized in research focused on the modulation of cholinergic activity and is relevant for studies investigating neurodegenerative diseases and muscle disorders. Its strong inhibition of ChE makes it a valuable tool for exploring the dynamics of acetylcholine in biological systems. -
AChE/BChE Inhibitor
Octahydroaminoacridine is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), serving as a valuable tool in cholinergic research. Its activity can enhance understanding of neurodegenerative conditions, particularly Alzheimer's disease (AD). This compound offers insight into mechanisms of cholinesterase inhibition, supporting the development of therapeutic strategies for cognitive disorders. -
Acetylcholinesterase Inhibitor
(E)-2-Nitrocinnamic acid is an effective acetylcholinesterase inhibitor. Its primary mechanism of action involves the modulation of acetylcholine levels, which is significant for neurochemical research. This compound is particularly relevant for studies related to Alzheimer's disease and other neurodegenerative disorders, providing valuable insights into potential therapeutic approaches. -
AChE Inhibitor
DCDQ is a potent inhibitor of acetylcholinesterase (AChE), demonstrating strong binding affinity for the 4EY7 protein with a binding energy of −8.2 kcal/mol. This compound is of significant interest in the research of Alzheimer's disease (AD), where AChE inhibition may enhance cholinergic transmission and potentially improve cognitive function. DCDQ serves as a valuable tool for investigating therapeutic strategies aimed at mitigating the effects of neurodegenerative disorders. -
AchE Inhibitor
Territrem C is a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 0.23 μM. This compound, categorized as an α-pyrone meroterpenoid, is derived from the fungus Penicillium sp. SK5GW1L. Territrem C is primarily utilized in biological research to study cholinergic signaling pathways and to explore potential therapeutic strategies for conditions associated with AChE dysfunction. -
AChE/BChE Inhibitor
AChE/BChE-IN-8 is an uncompetitive inhibitor of acetylcholinesterase (AChE) and a mixed inhibitor of butyrylcholinesterase (BChE), demonstrating Ki values of 0.788 μM and 2.364 μM against Electrophorus electricus AChE and equine BChE, respectively. This compound is capable of crossing the blood-brain barrier and exhibits low cytotoxicity, making it suitable for neurological research applications. AChE/BChE-IN-8 can be effectively utilized in studies focused on cholinergic signaling, neurodegenerative diseases, and the modulation of cholinergic activity. -
Cholinesterase Inhibitor
RX 67668 is a potent cholinesterase inhibitor, demonstrating an IC50 of 5 μM for both acetylcholinesterase (AChE) and butyrylcholinesterase. This compound effectively reverses neuromuscular blockade induced by D-tubocurarine. RX 67668 has applications as a muscle relaxant and is utilized in research focused on alleviating skeletal muscle fatigue.
